Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bendamustine plus rituximab for chronic cold agglutinin disease
2011-004835-30Phase 2Completed
- Sponsor
- Haugesund Hospital
- Start
- Aug 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bendamustine and rituximab in cold agglutinin disease (CAD) and Lymphoplasmacytic Lymphoma (LPL), sponsored by Haugesund Hospital. Primary endpoint: Rate of complete and partial responses. Started Aug 2012; status: completed.
02
Drugs
bendamustinerituximab
03
Conditions
cold agglutinin disease (CAD)Lymphoplasmacytic Lymphoma (LPL)
Beyond the preview
Go deeper on 2011-004835-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004835-30.